Daily Brief: Summit's $12m lifeline, Biohaven's speech anxiety pill, Crescendo's Humabody progress

News from pharma, biotech and healthcare

More From BioPortfolio on "Daily Brief: Summit's $12m lifeline, Biohaven's speech anxiety pill, Crescendo's Humabody progress"